l General Information |
Product Name | Sunitinib |
General description | Sunitinib is an indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. |
Synonym | N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide; SU-11248; Sutent; |
Purity | ≥99%(HPLC) | CAS Number | 557795-19-4 |
Formula | C22H27FN4O2 | Molecular Weight | 398.482 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | Orange or yellow solid |
Solubility(25℃) | DMSO | ≥20mg/mL |
Ethanol | Very slightly soluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Sunitinib is the orally bioavailable an indolinone-based tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation. This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells. |
Application | 1.Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. 2.Substances that inhibit or prevent the proliferation of neoplasms. |
l Packaging & Storage |
Packaging | 50mg; 250mg; 1g; |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
